ReviewClinical genitourinary cancer2018

Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development.

Thomas Powles et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.